Literature DB >> 10943866

Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjögren's syndrome salivary glands.

M Azuma1, K Aota, T Tamatani, K Motegi, T Yamashita, K Harada, Y Hayashi, M Sato.   

Abstract

OBJECTIVE: We have previously shown that specific enhancement in acinar cells of proteolytic activity induced by tumor necrosis factor alpha (TNFalpha) may be responsible for the destruction of the acinar structure in the salivary glands of patients with Sjögren's syndrome. Because matrix metalloproteinase 9 (MMP-9) is regulated by nuclear factor kappaB (NF-kappaB), we investigated the effect of a super-repressor form of inhibitor of nuclear factor kappaBalpha (srIkappaBalpha) on the suppression of TNFalpha-induced MMP-9 production in acinar cells.
METHODS: Two srIkappaBalpha complementary DNA (cDNA)-transfected acinar cell clones (ACMT-6 and ACMT-7) and 1 empty vector-transfected cell clone (ACpRc-1) were established. After treatment of cell clones with TNFalpha, the expression of MMP-9 was examined. In addition, the effect of TNFalpha on cell growth and the morphogenetic behavior of cell clones cultured on type IV collagen-coated dishes were examined.
RESULTS: TNFalpha induced the production of MMP-9 in the ACpRc-1 cell clone, but greatly suppressed MMP-9 production in ACMT-6 and ACMT-7 clones. No apparent cytotoxic effect of TNFalpha treatment was observed in these cell clones. When ACpRc-1 cells were seeded on type IV collagen-coated dishes in the presence of both TNFalpha and plasmin, type IV collagen interaction with the cells was lost and the cells entered apoptosis. However, even when ACMT-6 and ACMT-7 cells were cultured under the same culture conditions as those for ACpRc-1, these cell clones attached to the substrate and grew consistently without showing apoptosis. Conclusion. These observations indicate that suppression of TNFalpha-induced MMP-9 production by the introduction of srIkappaBalpha cDNA corrected the aberrant in vitro morphogenesis of acinar cells grown on type IV collagen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943866     DOI: 10.1002/1529-0131(200008)43:8<1756::AID-ANR12>3.0.CO;2-H

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  Role of nuclear factor kappaB in synovial inflammation.

Authors:  Ulf Müller-Ladner; Renate E Gay; Steffen Gay
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

Review 2.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.

Authors:  Joel W Nelson; Noel J Leigh; Rachel E Mellas; Andrew D McCall; Alfredo Aguirre; Olga J Baker
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-20       Impact factor: 4.249

Review 4.  Biologic therapy in Sjögren's syndrome.

Authors:  Qin Shao
Journal:  Clin Rheumatol       Date:  2020-10-27       Impact factor: 2.980

5.  TNF-α inhibits aquaporin 5 expression in human salivary gland acinar cells via suppression of histone H4 acetylation.

Authors:  Yoshiko Yamamura; Katsumi Motegi; Kouichi Kani; Hideyuki Takano; Yukihiro Momota; Keiko Aota; Tomoko Yamanoi; Masayuki Azuma
Journal:  J Cell Mol Med       Date:  2012-08       Impact factor: 5.310

Review 6.  Potential Role of Free Fatty Acids in the Pathogenesis of Periodontitis and Primary Sjögren's Syndrome.

Authors:  Yosuke Shikama; Yasusei Kudo; Naozumi Ishimaru; Makoto Funaki
Journal:  Int J Mol Sci       Date:  2017-04-14       Impact factor: 5.923

7.  Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's syndrome: a randomized, double-blind, placebo controlled cross-over study.

Authors:  Hubertus Seitsalo; Raija K Niemelä; Magdalena Marinescu-Gava; Tuija Vuotila; Leo Tjäderhane; Tuula Salo
Journal:  J Negat Results Biomed       Date:  2007-12-31

8.  Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome.

Authors:  Peter Willeke; Markus Gaubitz; Heiko Schotte; Christian Maaser; Wolfram Domschke; Bernhard Schlüter; Heidemarie Becker
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 9.  The future of biologic agents in the treatment of Sjögren's syndrome.

Authors:  Jiska M Meijer; Justin Pijpe; Hendrika Bootsma; Arjan Vissink; Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

10.  Differential immunohistochemical expression of type I collagen and matrix metalloproteinase 2 among major salivary glands of young and geriatric mice.

Authors:  Mehmet Kemal Tumer; Mustafa Cicek
Journal:  J Appl Oral Sci       Date:  2018-06-11       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.